Prosecution Insights
Last updated: October 21, 2026
Application No. 18/720,255

SUBSTITUTED FUSED BICYCLIC PYRIDINE CARBOXAMIDE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI

Final Rejection §102
Filed
Jun 14, 2024
Priority
Dec 17, 2021 — IN 202111059075 +2 more
Examiner
RICCI, CRAIG D
Art Unit
1611
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Pi Industries Ltd.
OA Round
2 (Final)
54%
Grant Probability
Moderate
3-4
OA Rounds
11m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allowance Rate
623 granted / 1161 resolved
-6.3% vs TC avg
Strong +53% interview lift
Without
With
+52.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
81 currently pending
Career history
1231
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
41.8%
+1.8% vs TC avg
§102
17.3%
-22.7% vs TC avg
§112
20.7%
-19.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1161 resolved cases

Office Action

§102
DETAILED ACTION Notice of AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election with traverse of Group I in the reply filed on 5/26/2026 is acknowledged. Applicant first traverses on the grounds that “the property or activity shared by the claimed compounds and the compounds of Larsen are entirely different” (Applicant Arguments, Page 26). It is irrelevant that the prior art compound taught by Larsen et al is disclosed as having an activity that is different from the disclosed activity of an identical compound newly claimed by Applicant. Applicant next argues that “claims 1 and 2 of the present application do not permit hydrogen to be one of the substituents of R5 and R6” as in Larsen et al. Of course, when the claims were restricted, R5 and R6 of Formula (I) could be hydrogen. As such, Applicant’s arguments are not found persuasive. The requirement is still deemed proper and is therefore made FINAL. Claims 15-17 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant’s election without traverse of a single species in the reply filed on 5/26/2026 is also acknowledged. The elected species read upon claims 1-2, 10 and 12. Claims 3-9, 11 and 13-14 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Expansion of Election of Species Requirement Applicant’s elected species, a compound of Formula (I) having the following structure: PNG media_image1.png 190 384 media_image1.png Greyscale , reads upon claims 1-2, 10 and 12. The elected species has been searched and is deemed to be free of the prior art and non-obvious. The closest prior art compound is CAS RN 1797757-19-7 (entered into STN on 7/09/2015) having the following structure: PNG media_image2.png 190 458 media_image2.png Greyscale , which differs from the instantly claimed compound as indicated by arrows. At the outset, CAS RN 1797757-19-7 is excluded from Formula (I) by proviso. And considering that CAS RN 1797757-19-7 is not identified as exhibiting any activity, it would not have been obvious to modify CAS RN 1797757-19-7 to arrive at Applicant’s elected compound species. Accordingly, the search has been expanded as called for under current Office Markush practice – a compound-by-compound search – to include at least a single additional species (M.P.E.P. § 803.02). In the instant case, two additional species were identified: PNG media_image3.png 180 717 media_image3.png Greyscale , a compound of Formula (I), wherein X is O; Z1 is CHR4-CHR4 wherein each R4 is independently hydrogen; Z2 is C(R4)2 wherein each R4 is independently hydrogen; R1 is hydroxy; R2 is hydroxy; R3 is hydrogen; R5 and R6 are each independently C1 alkyl; R7 and R8 are each independently hydrogen; and R9 is hydrogen – which reads on pending claims 1-2 and 12; and PNG media_image4.png 156 338 media_image4.png Greyscale , a compound of Formula (I), wherein X is O; Z1 is C(R4)2 wherein each R4 is independently hydrogen; Z2 is C(R4)2 wherein each R4 is hydrogen; R1 is hydrogen; R2 is C1 alkyl; R3 is hydrogen; R5 and R6 are each independently C1 alkyl; R7 and R8 are independently hydrogen and hydroxy; and R9 is hydrogen – which reads on pending claims 1-2. Rejections to those claims follows. Since the search has not been expanded beyond the single additional species identified above, claim 10, which is directed to the elected species but which does not include the single additional species, is objected to as indicated below, and has not been further examined. Claim Objections Claim 1 is objected to for the following reason: Claim 1 recites “A compound of formula (I)” (wherein the “f” in formula is lowercase). However, the compound is further identified as “Formula (I)” (wherein the “F” in formula is capitalized). Applicant is requested to amend the claim for consistency. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-2 and 12 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Ito et al (J Heterocyclic Chem 29:1037-1044, 1992). Claim 1 is drawn to a compound of formula (I) which embraces the following compound species: PNG media_image3.png 180 717 media_image3.png Greyscale wherein: X is O; Z1 is CHR4-CHR4 wherein each R4 is independently hydrogen; Z2 is C(R4)2 wherein each R4 is independently hydrogen; R1 is hydroxy; R2 is hydroxy; R3 is hydrogen; R5 and R6 are each independently C1 alkyl; R7 and R8 are each independently hydrogen; and R9 is hydrogen – which reads on pending claims 1-2. Ito et al teach the instantly claimed compound (Page 1040, Compound 14). Accordingly, claims 1-2 are anticipated. Claim 12 is drawn to an agrochemical composition comprising a compound of formula (I) according to claim 1 and at least one agrochemically acceptable auxiliary selected from the group consisting of inert carrier, surfactant, additive, solid diluent and liquid diluent. Ito et al further teach that “Compound 14... obtained from 1i by the... procedure” comprising 1i “and trimethyl methanetricarboxylate... in diglyme” (Page 1043, Column 1). As such, Ito et al teach a composition comprising a compound of formula (I) according to claim 1 and at least one agrochemically acceptable auxiliary (i.e., diglyme). Accordingly, claim 12 is also anticipated. Claims 1-2 are ADDITIONALLY rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS RN 2343221-37-2 (entered into STN on 6/23/2019). Claim 1 is drawn to a compound of formula (I) which embraces the following compound species: PNG media_image4.png 156 338 media_image4.png Greyscale , wherein: X is O; Z1 is C(R4)2 wherein each R4 is independently hydrogen; Z2 is C(R4)2 wherein each R4 is hydrogen; R1 is hydrogen; R2 is C1 alkyl; R3 is hydrogen; R5 and R6 are each independently C1 alkyl; R7 and R8 are independently hydrogen and hydroxy; and R9 is hydrogen – which reads on pending claims 1-2. The instantly claimed compound is taught by CAS RN 2343221-37-2. Accordingly, claims 1-2 are anticipated. Claim Objections Claim 10 is objected to as depending from a rejected base claim. Since the search has not been expanded beyond the additional species identified above, claim 10, which is directed to the elected species but which does not include the additional species, has not been further examined. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to CRAIG D RICCI whose telephone number is (571) 270-5864. The examiner can normally be reached on Monday through Thursday, and every other Friday, 7:30 am - 5:00 pm ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bethany Barham can be reached on (571) 272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CRAIG D RICCI/Primary Examiner, Art Unit 1611
Read full office action

Prosecution Timeline

Jun 14, 2024
Application Filed
Jun 16, 2026
Non-Final Rejection mailed — §102
Sep 16, 2026
Response Filed
Oct 19, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766085
EMULSIFIER COMPOSITION FOR PERSONAL CARE FORMULATION
3y 8m to grant Granted Oct 20, 2026
Patent 12767642
PROCESS FOR MANUFACTURING A MIXTURE COMPRISING A DIMERIC MACROCYCLE INTERMEDIATE OF A GADOLINIUM COMPLEX
2y 4m to grant Granted Oct 20, 2026
Patent 12760017
T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF
3y 1m to grant Granted Oct 13, 2026
Patent 12753180
SIRT6 ACTIVATORS
3y 0m to grant Granted Oct 06, 2026
Patent 12746306
HYALURONIC ACID DERIVATIVE AND USE THEREOF
4y 3m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
54%
Grant Probability
99%
With Interview (+52.6%)
3y 3m (~11m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1161 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month